靶向多种激酶通路：范式的转变。
Targeting multiple kinase pathways: a change in paradigm.
机构信息
CRUK Cambridge Research Institute, Addenbrooke's Hospital, Cambridge, United Kingdom.
出版信息
Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9.
Abstract
Anticancer drugs that target protein kinases include small molecule inhibitors and monoclonal antibodies. Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments. Increasingly, therapies are being designed to target multiple kinase pathways. This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents. In this review we discuss the principles of specifically targeting multiple kinase pathways with particular reference to angiogenic signaling pathways.
摘要
抗肿瘤药物中靶向蛋白激酶的药物包括小分子抑制剂和单克隆抗体。信号通路之间的反馈回路和串扰对癌症治疗的疗效有重大影响，而对靶向药物的耐药性是有效治疗的主要障碍。越来越多的治疗方法被设计用于靶向多个激酶途径。这可以通过使用同时抑制多个信号通路的单一药物或多种高选择性药物的联合来实现。在这篇综述中，我们讨论了针对多个激酶途径的具体靶向原则，特别提到了血管生成信号通路。
相似文献
1
Targeting multiple kinase pathways: a change in paradigm.靶向多种激酶通路：范式的转变。
Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9.
2
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.抗癌治疗的新范式：用激酶抑制剂靶向多种信号通路。
Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005.
3
Therapeutic protein kinase inhibitors.治疗性蛋白激酶抑制剂
Cell Mol Life Sci. 2009 Apr;66(7):1163-77. doi: 10.1007/s00018-008-8539-7.
4
Protein kinases as targets for cancer treatment.作为癌症治疗靶点的蛋白激酶。
Pharmacogenomics. 2007 Aug;8(8):1005-16. doi: 10.2217/14622416.8.8.1005.
5
Targeting cancer with small molecule kinase inhibitors.用小分子激酶抑制剂靶向治疗癌症。
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
6
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.开发针对妇科及其他恶性肿瘤患者信号转导的治疗方法所面临的挑战。
J Clin Oncol. 2003 May 15;21(10 Suppl):175s-186s. doi: 10.1200/JCO.2003.01.146.
7
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.PI3K和mTOR抑制剂：新一代靶向抗癌药物。
Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7.
8
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.表皮生长因子受体（EGFR）靶向治疗：单克隆抗体与酪氨酸激酶抑制剂。异同点
Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26.
9
Targeting the cancer kinome through polypharmacology.通过多药理学靶向癌症激酶组。
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.
10
Dissecting kinase signaling pathways.剖析激酶信号通路。
Drug Discov Today. 2007 Sep;12(17-18):717-24. doi: 10.1016/j.drudis.2007.07.019. Epub 2007 Aug 23.
引用本文的文献
1
Kinase signaling cascades: an updated mechanistic landscape.激酶信号级联反应：最新的机制全景
Chem Sci. 2025 Aug 19. doi: 10.1039/d5sc04657b.
2
Design, synthesis and pharmacological evaluation of 1,4-naphthoquinone- 1,2,3-triazole hybrids as new anticancer agents with multi-kinase inhibitory activity.1,4-萘醌-1,2,3-三唑杂化物作为具有多激酶抑制活性的新型抗癌剂的设计、合成及药理评价
Sci Rep. 2025 Feb 24;15(1):6639. doi: 10.1038/s41598-025-87483-w.
3
Anticancer Drug Discovery from Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway.基于靶向PI3K/AKT/mTOR信号通路的天然化合物的抗癌药物发现
Curr Med Chem. 2024 Oct 10. doi: 10.2174/0109298673325229240928040758.
4
Bacterial Histidine Kinase and the Development of Its Inhibitors in the 21st Century.细菌组氨酸激酶及其21世纪抑制剂的发展
Antibiotics (Basel). 2024 Jun 22;13(7):576. doi: 10.3390/antibiotics13070576.
5
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.利用癌症表型可塑性制定新型治疗策略。
J Clin Med. 2024 Jun 5;13(11):3337. doi: 10.3390/jcm13113337.
6
Development of Novel Class of Phenylpyrazolo[3,4-]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies.新型苯基吡唑并[3,4-d]嘧啶类化合物的开发，具有潜在的抗癌活性和基于对接研究的多靶点酶抑制作用。
Int J Mol Sci. 2023 Oct 9;24(19):15026. doi: 10.3390/ijms241915026.
7
Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.吗啉取代物对 ZSTK474 抑制 I 类 PI3K 同工型的结构影响：新型 MEK/PI3K 双功能抑制剂的研发。
Eur J Med Chem. 2022 Feb 5;229:113996. doi: 10.1016/j.ejmech.2021.113996. Epub 2021 Nov 14.
8
Targeting Protein Kinases Degradation by PROTACs.利用PROTACs靶向蛋白质激酶降解
Front Chem. 2021 Jun 30;9:679120. doi: 10.3389/fchem.2021.679120. eCollection 2021.
9
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.FAK 与 Wnt 信号通路在癌症中的串扰及其治疗意义。
Int J Mol Sci. 2020 Nov 30;21(23):9107. doi: 10.3390/ijms21239107.
10
Synthesis of histidine kinase inhibitors and their biological properties.组氨酸激酶抑制剂的合成及其生物学特性。
Med Res Rev. 2020 Jul;40(4):1440-1495. doi: 10.1002/med.21651. Epub 2019 Dec 5.
本文引用的文献
1
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.舒尼替尼每日一次持续给药方案用于细胞因子难治性转移性肾细胞癌患者的II期研究。
J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3.
2
Targeting the phosphoinositide 3-kinase pathway in cancer.靶向癌症中的磷酸肌醇3-激酶通路。
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
3
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.靶向癌症中的PI3K信号通路：机遇、挑战与局限
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
4
Sequential sorafenib and sunitinib for renal cell carcinoma.序贯索拉非尼和舒尼替尼治疗肾细胞癌。
J Urol. 2009 Jul;182(1):29-34; discussion 34. doi: 10.1016/j.juro.2009.02.119. Epub 2009 May 17.
5
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.凡德他尼与吉非替尼治疗晚期非小细胞肺癌患者的疗效比较：一项两部分、双盲、随机II期研究的结果
J Clin Oncol. 2009 May 20;27(15):2523-9. doi: 10.1200/JCO.2008.18.6015. Epub 2009 Mar 30.
6
Targeting the mTOR signaling network for cancer therapy.靶向mTOR信号网络用于癌症治疗。
J Clin Oncol. 2009 May 1;27(13):2278-87. doi: 10.1200/JCO.2008.20.0766. Epub 2009 Mar 30.
7
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.贝伐单抗联合吉西他滨和厄洛替尼治疗转移性胰腺癌的III期试验。
J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.
8
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.替西罗莫司与苹果酸舒尼替尼联合治疗晚期肾细胞癌的I期研究。
Clin Genitourin Cancer. 2009 Jan;7(1):24-7. doi: 10.3816/CGC.2009.n.004.
9
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.mTOR的活性位点抑制剂靶向mTORC1和mTORC2的雷帕霉素抗性输出。
PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.
10
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.厄洛替尼与贝伐单抗用于复发性或转移性头颈部鳞状细胞癌患者：一项I/II期研究
Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.
Zotero 插件